Astrana Health, Inc. (NASDAQ:ASTH) Receives Average Rating of “Moderate Buy” from Brokerages

Astrana Health, Inc. (NASDAQ:ASTH) has received a consensus recommendation of “Moderate Buy” from the eleven analysts that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $41.3333.

A number of equities analysts have weighed in on ASTH shares. Zacks Research cut shares of Astrana Health from a “hold” rating to a “strong sell” rating in a research report on Monday, November 10th. Barclays cut their target price on shares of Astrana Health from $36.00 to $26.00 and set an “equal weight” rating for the company in a research note on Monday, November 24th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Astrana Health in a research note on Monday. BTIG Research cut their price objective on Astrana Health from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Finally, Needham & Company LLC assumed coverage on Astrana Health in a report on Friday. They set a “buy” rating and a $28.00 target price for the company.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Covestor Ltd increased its stake in Astrana Health by 777.6% during the first quarter. Covestor Ltd now owns 2,001 shares of the company’s stock worth $62,000 after acquiring an additional 1,773 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Astrana Health by 323.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock worth $115,000 after purchasing an additional 3,517 shares during the last quarter. State of Wyoming acquired a new stake in shares of Astrana Health during the 2nd quarter worth about $132,000. AlphaQuest LLC raised its holdings in Astrana Health by 144.2% in the 1st quarter. AlphaQuest LLC now owns 4,883 shares of the company’s stock valued at $151,000 after buying an additional 2,883 shares during the period. Finally, US Bancorp DE lifted its position in Astrana Health by 21.3% in the first quarter. US Bancorp DE now owns 5,791 shares of the company’s stock valued at $180,000 after buying an additional 1,015 shares during the last quarter. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Astrana Health Stock Performance

Shares of ASTH stock opened at $22.31 on Friday. The company has a current ratio of 1.40, a quick ratio of 1.40 and a debt-to-equity ratio of 1.27. Astrana Health has a 12-month low of $20.12 and a 12-month high of $39.97. The business’s 50 day moving average is $26.70 and its two-hundred day moving average is $26.75. The company has a market capitalization of $1.26 billion, a P/E ratio of 117.43, a P/E/G ratio of 1.35 and a beta of 0.86.

Astrana Health (NASDAQ:ASTH) last announced its earnings results on Wednesday, January 10th. The company reported $0.50 earnings per share for the quarter. Astrana Health had a return on equity of 1.26% and a net margin of 0.33%.The business had revenue of $317.00 million during the quarter. Analysts expect that Astrana Health will post 1.15 EPS for the current fiscal year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.